| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Neuromyelitis optica (NMO) is an autoimmune inflammatory, neurodestructive disease primarily targeting the optic nerve and spinal cord. We evaluated the impact of sera of seropositive patients with NMO on the rodent optic nerve and retina. Serum which obtained from patients with seropositive NMO (AQP4+), decreased the expression of AQP4+ amd GFAP at the 7 days after the treatment. The gene expression of neurofilament in retina from the eye that was exposed to the AQP4+ sera at 14 days. Retrograde fluorogold-labeling on the retinal flatmount disclosed the significantly reduced number of retinal ganglion cells when the AQP4+ sera were applied. This has demonstrated that the sera from patients with seropositive NMO led to the regional astrocytic degeneration and inflammatory cell invasion in the optic nerve. The administration of human IgG reduced optic nerve degeneration in a rat model of NMO-optic neuritis.
|
